Teva Pharmaceutical Industries Ltd (TEVA)

2,663
+35(+1.33%)
  • Volume:
    676,306
  • Bid/Ask:
    2,663/2,667
  • Day's Range:
    2,630 - 2,679
  • Type:Equity
  • Market:Israel
  • ISIN:IL0006290147
  • S/N:629014

TEVA Overview

Prev. Close
2,628
Day's Range
2,630-2,679
Revenue
51.34B
Open
2,638
52 wk Range
2,560-4,390
EPS
2.08
Volume
676,306
Market Cap
29.45B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,756,739
P/E Ratio
12.65
Beta
1.46
1-Year Change
-21.32%
Shares Outstanding
1,103,007,168
Next Earnings Date
Feb. 10, 2022
What is your sentiment on Teva Pharmaceutical Industries Ltd?
or
Vote to see community's results!

Teva Pharmaceutical Industries Ltd Company Profile

Employees
37736
Market
Israel

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system and pain area include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company’s products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell S.A. to develop mdc-IRM, a risperidone extended-release injectable suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.